These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15577570)

  • 1. Value-based medicine: a new paradigm to evaluate treatments for vitreoretinal diseases and other medical interventions.
    Busbee BG; Brown GC; Brown MM
    Int Ophthalmol Clin; 2004; 44(4):155-72. PubMed ID: 15577570
    [No Abstract]   [Full Text] [Related]  

  • 2. Value-based medicine and vitreoretinal diseases.
    Brown MM; Brown GC; Sharma S
    Curr Opin Ophthalmol; 2004 Jun; 15(3):167-72. PubMed ID: 15118501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The macroeconomics of vitreoretinal diseases.
    Ko GJ; Brown MM; Brown GC
    Curr Opin Ophthalmol; 2005 Jun; 16(3):184-90. PubMed ID: 15870577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare costs, buyer alert.
    Brown MM; Brown GC; Leiske HB; Lieske PA
    Curr Opin Ophthalmol; 2011 May; 22(3):149-51. PubMed ID: 21460725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vitreoretinal outpatient surgery: clinical and financial considerations].
    Creuzot-Garcher C; Aubé H; Candé F; Dupont G; Guillaubey A; Malvitte L; Arnavielle S; Bron A
    J Fr Ophtalmol; 2008 Nov; 31(9):871-6. PubMed ID: 19107058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical malpractice litigation in the management of vitreoretinal diseases.
    Kraushar MF
    Arch Ophthalmol; 1987 Feb; 105(2):187-90. PubMed ID: 3813947
    [No Abstract]   [Full Text] [Related]  

  • 7. Preference-based comparative effectiveness and cost–effectiveness: a review and relevance of value-based medicine for vitreoretinal interventions.
    Brown MM; Brown GC; Lieske HB; Lieske PA
    Curr Opin Ophthalmol; 2012 May; 23(3):163-74. PubMed ID: 22487884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strengthen basic research to improve diagnosis and therapeutics of vitreoretinal disease].
    Tang SB
    Zhonghua Yan Ke Za Zhi; 2003 Nov; 39(11):641-4. PubMed ID: 14989229
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current topics in vitreoretinal diseases].
    Ohji M
    Nippon Ganka Gakkai Zasshi; 2005 Mar; 109(3):113-4. PubMed ID: 15828269
    [No Abstract]   [Full Text] [Related]  

  • 10. Current concepts in diagnosis and treatment of vitreoretinal diseases 12th meeting of the Club Jules Gonin, Crans-Montana, March 17-21, 1980.
    Dev Ophthalmol; 1981; 2():1-406. PubMed ID: 7262388
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cost recovery for the treatment of retinal and vitreal diseases by pars plana vitrectomy under the German DRG system].
    Framme C; Franz D; Mrosek S; Helbig H
    Ophthalmologe; 2007 Oct; 104(10):866-74. PubMed ID: 17882428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitreoretinal disease in the coming decade.
    Chiang A; Haller JA
    Curr Opin Ophthalmol; 2010 May; 21(3):197-202. PubMed ID: 20224401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward affordable, sustainable eye care.
    Sommer A
    Int Ophthalmol; 1994-1995; 18(5):287-92. PubMed ID: 7607810
    [No Abstract]   [Full Text] [Related]  

  • 14. We are producers of patient value and financial value.
    Brown GC
    Curr Opin Ophthalmol; 2013 May; 24(3):181-2. PubMed ID: 23549600
    [No Abstract]   [Full Text] [Related]  

  • 15. [Value-based medicine in ophthalmology].
    Hirneiss C; Neubauer AS; Tribus C; Kampik A
    Ophthalmologe; 2006 Jun; 103(6):493-500. PubMed ID: 16763866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Eye Care Technology Forum. Impacting eye care cost and effectiveness.
    Ellwein LB
    Ophthalmology; 1994 Jan; 101(1):199-201. PubMed ID: 8302556
    [No Abstract]   [Full Text] [Related]  

  • 17. Vitreomacular disorders: pathogenesis and treatment.
    Johnson MW; Brucker AJ; Chang S; Gandorfer A; Kampik A; Kuppermann BD; Russell SR; Spaide RF; Thompson JT
    Retina; 2012 Sep; 32 Suppl 2():S173. PubMed ID: 22929315
    [No Abstract]   [Full Text] [Related]  

  • 18. How to interpret a healthcare economic analysis.
    Brown MM; Brown GC
    Curr Opin Ophthalmol; 2005 Jun; 16(3):191-4. PubMed ID: 15870578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitreoretinal emergencies.
    Reichel E
    Am Fam Physician; 1995 Oct; 52(5):1415-9. PubMed ID: 7572564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Floaters and the quality of life.
    Sebag J
    Am J Ophthalmol; 2011 Jul; 152(1):3-4.e1. PubMed ID: 21703388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.